Lokivetmab

浏览次数：2

货号： UA010875

大包装询价

产品介绍引用文献(0) 评论(0)

产品规格

物种

Canine
分子别名

Cytopoint
表达宿主

CHO
分子量

25-27 kDa (Light Chain) & 53-55 kDa (Heavy Chain) (Reducing)
纯度

＞95% by SDS-PAGE
内毒素含量

<0.1EU/μg
标记

Unconjugated
性状

Lyophilized Powder
缓冲体系

PBS, pH7.4.
溶解方法

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
文献引用

1. Matthew Krautmann. Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs. Vet Immunol Immunopathol. 2023 Apr:258:110574.

背景介绍

Lokivetmab is a caninized anti-IL-31 mAb that binds and neutralizes canine IL-31, resulting in reduced skin lesions and inhibition of pruritus in dogs with AD or allergic dermatitis. Lokivetmab is the first mAb approved for use in dogs with canine AD and allergic dermatitis by regulatory agencies worldwide. Lokivetmab targets canine IL-31 specifically and does not bind to murine or human IL-31 or to any other canine proteins. After s.c. administration, lokivetmab is absorbed and incorporated into the pool of circulating antibodies. The long terminal elimination half-life of lokivetmab in dogs of 16.5 ± 3.0 days is due to recycling via the FcRn receptor and allows for monthly injections to maintain efficacy. Elimination by catabolism is identical to any endogenous protein. Lokivetmab binds at a single epitope on canine IL-31, forming a mAb:IL-31 complex having pharmacokinetics and elimination like unbound lokivetmab.

生物活性
- Measured by its binding ability in a functional ELISA. When Lokivetmab(Anti-Canine IL-31Recombinant Antibody) is immobilized 0.5µg/mL (100µL/well), Recombinant Canine IL-31 binds with an EC50 of 0.07-1ng/ml.
电泳(SDS-PAGE)
- 2μg (R: reducing condition).